We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.23B
1-Year Est. Return 81.32%
This Fund
S&P 500
This Quarter Est. Return
-15.77%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$584M
AUM Growth
-$130M
Cap. Flow
-$2.08M
Cap. Flow %
-0.36%
Top 10 Hldgs %
80.9%
Holding
33
New
4
Increased
7
Reduced
2
Closed
4

Top Buys

Rank Stock Value
1
MIRM icon
Mirum Pharmaceuticals
MIRM
+$30M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$5.74M
3
SILK
Silk Road Medical, Inc. Common Stock
SILK
+$3.98M
4
BPMC
Blueprint Medicines
BPMC
+$3.26M
5
AERI
Aerie Pharmaceuticals
AERI
+$2.29M

Top Sells

Rank Stock Value
1
GKOS icon
Glaukos
GKOS
+$22.6M
2
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$12.6M
3
NBRV
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
+$8.38M
4
MRUS
Merus
MRUS
+$7.25M
5
CRVS icon
Corvus Pharmaceuticals
CRVS
+$6.27M

Sector Composition

Rank Sector Weight
1 Healthcare 73.42%
2 Technology 10.28%
3 Communication Services 9.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INGN icon
1
Inogen
INGN
$171M
$170M 29.13%
3,549,321
– –
AAPL icon
2
Apple
AAPL
$4.95T
$60M 10.28%
1,071,152
– –
CABO icon
3
Cable One
CABO
$224M
$56.5M 9.67%
45,000
– –
MIST icon
4
Milestone Pharmaceuticals
MIST
$141M
$49.9M 8.55%
2,674,470
– –
MORF
5
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$47.9M 8.21%
2,645,446
– –
MIRM icon
6
Mirum Pharmaceuticals
MIRM
$6.96B
$24.6M 4.21%
+2,445,147
New +$30M
FOLD
7
DELISTED
Amicus Therapeutics
FOLD
$18.6M 3.18%
2,317,870
– –
SPNE
8
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$16M 2.74%
1,308,037
– –
SIBN icon
9
SI-BONE Inc
SIBN
$756M
$15.8M 2.7%
892,684
– –
ETTX
10
DELISTED
Entasis Therapeutics Holdings Inc.
ETTX
$13M 2.23%
2,181,843
– –
AERI
11
DELISTED
Aerie Pharmaceuticals
AERI
$12.9M 2.21%
670,036
+100,000
+18% +$2.29M
BPMC
12
DELISTED
Blueprint Medicines
BPMC
$12.5M 2.15%
170,667
+37,691
+28% +$3.26M
AKBA icon
13
Akebia Therapeutics
AKBA
$343M
$12.2M 2.08%
3,100,000
– –
INSP icon
14
Inspire Medical Systems
INSP
$1.47B
$10.7M 1.83%
175,000
– –
CRVS icon
15
Corvus Pharmaceuticals
CRVS
$1.09B
$8.81M 1.51%
2,927,560
-1,492,956
-34% -$6.27M
SILK
16
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$7.97M 1.37%
245,000
+100,000
+69% +$3.98M
PTGX icon
17
Protagonist Therapeutics
PTGX
$8.72B
$5.75M 0.99%
479,074
+455,173
+1,904% +$5.74M
KIDS icon
18
OrthoPediatrics
KIDS
$509M
$5.33M 0.91%
151,259
-9,483
-6% -$329K
STIM icon
19
Neuronetics
STIM
$126M
$5.22M 0.89%
628,348
+45,550
+8% +$498K
SPRO icon
20
Spero Therapeutics
SPRO
$68.3M
$4.94M 0.85%
465,983
– –
XLRN
21
DELISTED
Acceleron Pharma
XLRN
$4.73M 0.81%
119,708
– –
XENT
22
DELISTED
Intersect ENT, Inc
XENT
$3.7M 0.63%
217,709
+80,824
+59% +$1.47M
VRNA
23
DELISTED
Verona Pharma
VRNA
$3.38M 0.58%
740,740
– –
CRNX icon
24
Crinetics Pharmaceuticals
CRNX
$8.87B
$2.03M 0.35%
135,009
– –
MYOK
25
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$1.58M 0.27%
+30,348
New +$1.61M
1
2

Similar funds

HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
CA
Cullinan Associates Louisville, Kentucky $1.24B AUM 28.12% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
WTA
Washington Trust Advisors Wellesley, Massachusetts $1.24B AUM 22.58% 1-Year Est. Return
CCA
Clearwater Capital Advisors Hoffman Estates, Illinois $1.24B AUM 15.23% 1-Year Est. Return

Novo Holdings A/S's Q3 2019 Portfolio in Review

As of Q3 2019, Novo Holdings A/S held 33 positions worth $584M, down 18% from $714M the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Novo Holdings A/S's Q3 2019 filing shows 4 new, 7 increased, 2 reduced and 4 closed positions. Its largest new stake was Mirum Pharmaceuticals: 2,445,147 shares worth $24.6M. The largest sale was Glaukos, an estimated $22.6M.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 80% a quarter earlier, followed by Technology and Communication Services.

  • Novo Holdings A/S's largest Q3 2019 buy was Mirum Pharmaceuticals: 2,445,147 shares worth $24.6M.
  • Novo Holdings A/S added most to Protagonist Therapeutics in Q3 2019, an estimated $5.74M increase.
  • Novo Holdings A/S's biggest Q3 2019 reduction was Corvus Pharmaceuticals, cutting an estimated $6.27M.
  • Novo Holdings A/S fully exited Glaukos in Q3 2019, selling an estimated $22.6M.
  • Novo Holdings A/S's ten largest holdings make up 81% of its $584M portfolio in Q3 2019.
  • Novo Holdings A/S opened 4 new positions and closed 4 in Q3 2019.
  • Novo Holdings A/S's portfolio value fell 18% quarter-over-quarter to $584M.

Based on Novo Holdings A/S's 13F filing for Q3 2019, filed 14 Nov 2019.